H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS: